

**CLAIMS**

1. Use of an antagonist of at least one receptor chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor, with the exception of metronidazole, for the preparation of a pharmaceutical composition for treating rosacea.
- 10 2. Use according to Claim 1, characterized in that the said compound is an antagonist of two receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
- 15 3. Use according to Claim 1, characterized in that the said compound is an antagonist of three receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
- 20 4. Use according to Claim 1, characterized in that the said compound is an antagonist of four receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
- 25 5. Use according to Claim 1, characterized in that the said compound is an antagonist of five receptors chosen from the group comprising the beta-adrenergic receptors, the AT1 receptor, the 5-HT2 receptor, the 5-HT5 receptor and the galanin receptor.
- 30 6. Use according to any one of Claims 1 to 5, characterized in that the said compound is at least one antagonist of the beta-adrenergic receptors and in that it is chosen from the group comprising metropobol, esmolol, acebutolol, timolol, pindolol and labetolol.

7. Use according to any one of Claims 1 to 5, characterized in that the said compound is at least one antagonist of the AT1 receptor and in that it is chosen from the group comprising candesartan, cilexil,  
5 losartan, irbesartan, telmisartan, valsartan and eprosartan.
8. Use according to any one of Claims 1 to 5, characterized in that the said compound is at least one antagonist of the 5-HT2 and 5-HT5 receptors and in that it is chosen from the group comprising a compound chosen from the group comprising ketanserin, trazodone and risperidone.  
10
- 15 9. Use according to any one of Claims 1 to 8, characterized in that the said pharmaceutical composition is a dermatological composition for topical application.
- 20 10. Use according to any one of Claims 1 to 9, characterized in that the composition is for treating at least one stage of rosacea.
11. Use according to any one of Claims 1 to 10, characterized in that the composition is for treating  
25 the first stage of rosacea.
12. Use according to any one of Claims 1 to 11, characterized in that the composition is for treating  
30 the second stage of rosacea.
13. Use according to any one of Claims 1 to 12, characterized in that the composition is for treating the third stage of rosacea.  
35
14. Use according to any one of Claims 1 to 13, characterized in that the composition is for treating the fourth stage of rosacea.

15. Use according to any one of Claims 1 to 14, characterized in that the said composition contains from 0.0001% to 20% by weight, preferably from 0.1% to 2% and more preferentially from about 0.75% to 1% by 5 weight of the said antagonist.

16. Use according to any one of Claims 1 to 15, characterized in that the said composition also contains another active agent chosen from the group of 10 antibiotics, antibacterial agents, antiviral agents, antiparasitic agents, antifungal agents, anaesthetics, analgesics, antiallergic agents, retinoids, free-radical scavengers, anti-pruriginous agents, keratolytic agents, anti-seborrhoeic agents, antihistamines, 15 sulfides, immunosuppressant products and anti-proliferative products.

17. Use according to any one of Claims 1 to 16, characterized in that the composition contains an 20 additive chosen from the group of sequestrants, antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, dyes, common mineral or organic acids or bases, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, 25 essential fatty acids, sphingolipids, self-tanning compounds, calmatives and skin-protecting agents, pro-penetrating agents and gelling agents, or a mixture thereof.